Equities

Halberd Corp

HALB:PKC

Halberd Corp

Actions
  • Price (USD)0.0055
  • Today's Change0.000 / 5.77%
  • Shares traded445.26k
  • 1 Year change-42.11%
  • Beta-3.9943
Data delayed at least 15 minutes, as of Sep 20 2024 20:29 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Halberd Corporation is a holding company. The Company is engaged in the acquisition vehicle for established businesses. It is also developing treatments for neurodegenerative diseases, such as post-traumatic stress disorder/chronic traumatic encephalopathy (PTSD/ CTE), Alzheimer’s disease and Parkinson’s disease. It has two issued patents and four provisional patent applications related to the extracorporeal treatment of blood-borne diseases and cerebrospinal fluid related diseases, with particular focus on the treatment and rapid detection of Covid-19 and other viruses. Its Sequential Dialysis Technique is a methodology that physically removes the pathophysiologic basis of the disease, eliminating it without side effects. The Company’s wholly owned subsidiary is Alaric Corporation.

  • Revenue in USD (TTM)281.24k
  • Net income in USD25.34k
  • Incorporated2020
  • Employees3.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TNF Pharmaceuticals Inc0.00-7.07m3.01m9.00--0.1296-----5.53-5.530.0010.280.00----0.00-25.59-76.20-31.13-84.38--7.64---4,290.96----0.00------49.15------
Phio Pharmaceuticals Corp0.00-8.68m3.06m8.00--0.48-----23.77-23.770.007.400.00----0.00-98.62-71.92-126.86-84.15-------253,785.70----0.00------5.70--0.00--
Allarity Therapeutics Inc0.00-12.82m3.19m5.00--0.1331-----2,217.58-2,217.580.0016.980.00----0.00-52.54---110.73--------------0.0626------3.02------
CTT Pharmaceutical Holdings Inc0.00-1.67m3.22m0.00--1.73-----0.0822-0.08220.000.03460.00-------317.2813.49-448.83304.48------------0.00-------3,454.52------
Revelation Biosciences Inc0.00-15.90m3.23m9.00--1.24-----29.75-29.750.000.69390.00----0.00-112.35---253.32--------------0.00------98.89------
Bone Biologics Corp0.00-5.12m3.28m2.00--0.823-----10.26-10.260.002.210.00----0.00-94.66-98.31-119.03--------------0.00-------502.76------
Halberd Corp281.24k25.34k3.31m3.002.24--130.3311.760.00230.00230.0018-0.00020.14490.03032.52--1.31--4.58--50.00--9.01--0.26611.351.02--271.52---60.11------
Lipella Pharmaceuticals Inc507.20k-4.14m3.40m5.00--1.90--6.71-0.6188-0.61880.0740.2240.1788--16.01101,440.00-146.02---169.27-------816.72------0.00--144.15---77.81------
Tharimmune Inc0.00-8.88m3.44m2.00--0.4899-----55.46-55.460.006.110.00----0.00-138.06---181.81--------------0.00-------9.98------
Talis Biomedical Corp408.00k-51.03m3.46m99.00--0.0712--8.49-28.02-28.020.22426.690.0042--1.534,121.21-52.13-68.18-57.23-74.2295.10---12,506.37-1,615.96----0.00---55.65-2.2445.13---1.83--
Petros Pharmaceuticals Inc4.12m-20.64m3.60m21.00--0.4323--0.8747-6.54-6.541.000.9880.15290.67951.89196,223.30-26.18-32.43-39.25-68.0570.2162.04-171.23-201.701.26--0.4539---2.83-16.1531.06------
Virpax Pharmaceuticals Inc0.00-17.23m3.62m7.00---------13.51-13.510.00-0.98470.00----0.00-185.82-87.52-362.29-116.56-----------1,596.37--------29.84------
Data as of Sep 20 2024. Currency figures normalised to Halberd Corp's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.